HCPCS Level II code J2805 denotes a 5 microgram injection of sincalide, a synthetic cholecystokinin analog used to provoke gallbladder contraction for diagnostic imaging. Nationally, this code matters for facilities that perform hepatobiliary and gallbladder functional studies because it identifies a specific injectable diagnostic agent that influences both clinical workflows and billing documentation.

Key payers commonly engaged with this service include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find an overview of coding intent, typical sites of service, and the clinical context for use. The publication also summarizes payer coverage patterns and benchmarks where available, highlights relevant policy updates affecting injectable diagnostic agents, and situates J2805 within service-line and billing workflows.

This summary is intended to inform billing staff, revenue managers, and clinical leaders about the role of J2805 in diagnostic imaging encounters, provide clarity on documentation expectations, and present the types of analyses typically included in a full report (coverage considerations, reimbursement benchmarks, and policy notes). Data not available in the input will be noted where applicable in the complete publication.